Jefferies assumed coverage of Immatics (IMTX) with a Buy rating and $18 price target The firm thinks the company is at an inflection point. The company’s cutaneous melanoma readout this year “is a major de-risking point” for the Jefferies’ work suggests a high likelihood of success, the analyst tells investors in a research note. The firm believes this alone can drive near-term upside in the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance
- Immatics sees cash runway into 2028
- Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
- Immatics price target raised to $25 from $23 at Mizuho
- Immatics’ treatment of Stage II and higher CM granted FDA orphan designation